AR and triple-negative breast carcinoma: As another hormonal receptor, the androgen receptor (AR) was expressed in 70–85% of all breast cancer cases [3], and that ratio was about 10–63% in triple-negative breast cancer (TNBC), which did not express ER, PR, or HER2 [4,5,6].